Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 5 January 2018

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

FIT Biotech Oy    

Published: 09:00 CET 05-01-2018 /GlobeNewswire /Source: FIT Biotech Oy / : FITBIO /ISIN: FI4000148606

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

FIT Biotech Oy

Company release January 5, 2018 at 10:00 AM EET

Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy ("Company") and Bracknor Investment ("Bracknor") the Company's Board of Directors have resolved on January 4, 2018 to approve Bracknor's request relating to the funding programme to convert EUR 60,000 worth of Convertible Capital Notes into the Company's K shares.

Due to the conversion of the Convertible Capital Notes, the Company transfers 6,475,984 K shares owned by the Company to Bracknor with the conversion price of EUR 0.00927 per share and the reserve for invested unrestricted equity of the Company will be increased by EUR 59,999.99. The Board authorization is based on Extraordinary General Meeting December 14, 2017.

The K shares will be admitted to trading on First North Finland on or about January 8, 2018.


Board of Directors

For further information:
Chairman of the Board of Directors Rabbe Slätis
E-mail: rabbe.slatis@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

Principal media


This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: FIT Biotech Oy, Biokatu 8, Tampere FI-33520, Finland
If you would like to unsubscribe and stop receiving these e-mails click here.